Mass General Brigham
Health Plan

Topical Immunomodulators
Effective 05/01/2023

Plan	☐ MassHealth UPPL ☒Commercial/Exchange	**Program Type**	☐ Prior Authorization ☐ Quantity Limit ☒ Step Therapy
Benefit	☒ Pharmacy Benefit ☐ Medical Benefit		
Specialty Limitations	N/A		
Contact Information	**Medical and Specialty Medications** All Plans | Phone: 877-519-1908 | Fax: 855-540-3693		
	Non-Specialty Medications All Plans | Phone: 800-711-4555 | Fax: 844-403-1029		
Exceptions	N/A		

Overview
Prescriptions that meet the initial step therapy requirements will adjudicate automatically at the point of sale. If the prescription does not meet the initial step therapy requirements, the prescription will deny with a message indicating that prior authorization (PA) is required. Refer to the criteria below and submit a PA request for the members who do not meet the initial step therapy requirements at the point of sale.

Initial Step-Therapy Requirements:
First-Line: Medications listed on first-line are covered without prior-authorization.
Second-Line: Second-line medications will pay if the member has filled at least two first-line medications or a second-line medication within the past 180 days.

Coverage Guidelines

FIRST-LINE	SECOND-LINE
Generic corticosteroids (see appendix below)	Pimecrolimus 1% Cream Tacrolimus 0.03% & 0.1% ointment Nujo 0.1% (tacrolimus) solution

If a member does not meet the initial step therapy requirements, then approval of a second-line medication will be granted if the member meets the following criteria:

1. The member has a diagnosis of atopic dermatitis or psoriasis **AND**
2. The member is 2 years of age or older **AND**
3. The member has previously tried at least TWO (2) medium, high, or very high potency topical corticosteroids AND has had a documented side effect, allergy, or treatment failure with BOTH agents

Limitations
1. Approvals will be granted for 12 months

2. A quantity limit of 30 grams per month applies.

Appendix

Topical Corticosteroid Reference (not all inclusive)

Very High Potency	Dosage Form	Strength
augmented betamethasone dipropionate (Diprolene)	Ointment	0.05%
clobetasol propionate (Temovate, Olux)	Cream, Gel, Ointment, Sol, Foam	0.05%
diflorasone diacetate (Psorcon)	Ointment	0.05%

High Potency	Dosage Form	Strength
amcinonide	Cream, Lotion, Ointment	0.1%
augmented betamethasone dipropionate (Diprolene AF)	Cream	0.05%
Betamethasone dipropionate	Cream, Ointment	0.05%
Betamethasone valerate	Ointment	0.1%
Desoximetasone (Topicort)	Cream, Ointment	0.25%
Desoximetasone (Topicort)	Cream, Gel	0.05%
diflorasone diacetate (Psorcon)	Cream	0.05%
Fluocinonide	Cream, Gel, Ointment, Solution	0.05%
Fluocinonide emollient base	Cream	0.05%
Triamcinolone acetonide (Kenalog)	Cream, Ointment	0.5%

Medium Potency	Dosage Form	Strength
Betamethasone dipropionate (Diprosone)	Lotion	0.05%
Betamethasone valerate	Cream, Lotion	0.1%
Desoximetasone (Topicort LP)	Cream	0.05%
Fluocinolone acetonide (Synalar)	Cream, Ointment	0.025%
Hydrocortisone valerate	Cream, Ointment	0.2%
Mometasone furoate (Elocon)	Ointment	0.1%
Triamcinolone acetonide (Kenalog)	Cream, Lotion, Ointment	0.025%
Triamcinolone acetonide (Kenalog)	Cream, Lotion, Ointment	0.1%

References

1. Elidel (pimecrolimus) [prescribing information]. Bridgewater, NJ: Valeant Pharmaceuticals; December 2017
2. Protopic (tacrolimus) [prescribing information]. Madison, NJ: LEO Pharma Inc; November 2016.
3. Hanifin JM, Cooper KD, Ho VC, Kang S, Krafchik BR, Margolis DJ, et al. Guidelines of Care for Atopic Dermatitis. J Am Acad Dermatol. 2004 Mar;50(3):391-404.
4. Lebwohl M, Freeman AK, Chapman MS, et al. Tacrolimus ointment is effective for facial and intertriginous psoriasis. J Am Acad Dermatol 2004; 51:723.
5. Feldman SR. Treatment of psoriasis. In: Basow DS (Ed.). UpToDate [database on the internet]. 2015. Available at: http://www.utdonline.com/utd/index/do
6. Weston WL, Howe W. Treatment of atopic dermatitis (eczema). In: Basow DS (Ed). UpToDate [database on the internet]. 2015. Available at: http://www.utdonline.com/utd/index/do
7. National Psoriasis Foundation. Psoriasis [webpage on the internet]. 2014. Available at: http://www.psoriasis.org/psoriasis

8. Eichenfield LF, Tom WL, Berger TG, Krol A, Paller AS, Schwarzenberger K, et al. Guidelines of care for the management of atopic dermatitis. Section 2: Management and treatment of atopic dermatitis with topical therapies. J Am Acad Dermatol. 2014; 71:116-32.
9. Margolis DJ, Abuabara K, Hoffstad OJ, Wan J, Raimondo D, Bilker WB. Association between malignancy and topical use of pimecrolimus. JAMA Dermatol. 2014. Doi:10.1001/jamadermatol.2014.4305

Review History

06/27/05 – Updated
04/24/06 – Reviewed
04/23/07 – Reviewed
04/28/08 – Reviewed
04/27/09 – Updated
04/26/10 – Updated
04/25/11 – Updated
04/23/12 – Reviewed
04/22/13 – Reviewed
04/28/14 – Updated
03/09/15 – Tacrolimus generic
04/27/15 – Reviewed
04/25/16 – Reviewed
06/26/17 – Updated
02/26/18 – Reviewed
02/20/19 – Updated
11/16/2020 - Updated; separated out MH vs. Comm/Exch criteria due to MH partial unified formulary.
02/08/2023 – Reviewed and Updated for Feb P&T; added new drug Nujo as a second line agent. Effective 05/01/2023